12.2 Cardiovascular & Metabolic Risk Screening

12.2 Cardiovascular & Metabolic Risk Screening

Cardiovascular disease (CVD) and metabolic disorders, including type 2 diabetes mellitus (T2DM), are primary drivers of morbidity in the Gulf region. Systematic risk screening and early identification are essential clinical practices for family physicians.

Hypertension Screening and Blood Pressure Classification

Hypertension is a silent, progressive disease that significantly increases the risk of stroke, myocardial infarction, and chronic kidney disease.

• UAE MOHAP Guidelines: Screen all asymptomatic adults starting at age 30, repeated every 3 years if blood pressure is normal.
• USPSTF Guidelines: Screen all adults aged >= 18 years. Annual screening is indicated for adults aged >= 40 years or those with risk factors (e.g., obesity). For low-risk adults aged 18 to 39 years with normal BP, screening is recommended every 3 to 5 years.
• Diagnosis Confirmation: To confirm hypertension and rule out white-coat or masked hypertension, Ambulatory Blood Pressure Monitoring (ABPM) or Home Blood Pressure Monitoring (HBPM) is required before initiating long-term therapy.
• AHA/ACC Blood Pressure Classification Table:

  BP Category	Systolic BP (mmHg)	Diastolic BP (mmHg)
  Normal	< 120	and < 80
  Elevated	120–129	and < 80
  Stage 1 Hypertension	130–139	or 80–89
  Stage 2 Hypertension	>= 140	or >= 90

---

Type 2 Diabetes Mellitus (T2DM) Screening

The high regional prevalence of insulin resistance necessitates low screening thresholds.

• UAE Guidelines: The Emirates Diabetes Society advocates initiating screening at age 30, repeated every 3 years if results are normal.
• ADA and USPSTF Guidelines: The ADA recommends universal screening starting at age 35, while the USPSTF advises screening asymptomatic, overweight/obese adults aged 35 to 70 years.
• Risk-Based Screening: Screen at any age in adults with a BMI >= 25 kg/m² (>= 23 kg/m² in Asian/Middle Eastern populations) who exhibit >= 1 risk factor (e.g., first-degree relative with T2DM, physical inactivity, PCOS, high-risk ethnicity, history of gestational diabetes, or hypertension).
• Diagnostic Criteria for Prediabetes and Diabetes:

  Status	HbA1c (%)	Fasting Plasma Glucose (FPG)	2-Hour Oral Glucose Tolerance (OGTT)
  Normal	< 5.7	< 5.6 mmol/L (100 mg/dL)	< 7.8 mmol/L (140 mg/dL)
  Prediabetes	5.7–6.4	5.6–6.9 mmol/L (100–125 mg/dL)	7.8–11.0 mmol/L (140–199 mg/dL)
  Diabetes	>= 6.5	>= 7.0 mmol/L (126 mg/dL)	>= 11.1 mmol/L (200 mg/dL)

---

Lipid Screening and Cardiovascular Risk Assessment

Dyslipidemia is a key driver of coronary artery disease. Lipid screening allows for the estimation of atherosclerotic cardiovascular disease (ASCVD) risk.

• Screening Protocols:
  • AHA/ACC: Recommends calculating the 10-year ASCVD risk score every 4 to 6 years in adults aged 20 to 79.
  • USPSTF: Recommends screening lipid levels in adults aged 40 to 75 to assess cardiovascular risk.
  • Statins in Primary Prevention: Prescribe a moderate-intensity statin to adults aged 40 to 75 with no prior history of CVD, who have >= 1 CVD risk factor (dyslipidemia, diabetes, hypertension, or smoking), and a calculated 10-year ASCVD risk >= 10%.
  • UAE Guidelines: Recommend lipid panels starting at age 30 as part of periodic health screening, or earlier in patients with a family history of premature coronary artery disease.

---

Levels of Prevention in Clinical Practice

Interventions in preventive medicine are divided into five distinct tiers based on the timing and target of the prevention:

1. Primordial Prevention:
   • Targets the social, economic, and environmental conditions that lead to the development of risk factors themselves.
   • Example: Establishing pedestrian-friendly urban planning to reduce community obesity rates, or taxing sugar-sweetened beverages.
2. Primary Prevention:
   • Aims to prevent the initial onset of disease in healthy individuals by addressing specific risk factors.
   • Example: Administering childhood immunizations (e.g., HPV, HBV), smoking cessation counseling, and prescribing low-dose aspirin in high-risk patients to prevent their first myocardial infarction.
3. Secondary Prevention:
   • Involves early detection and treatment of asymptomatic or subclinical disease to prevent progression and clinical manifestation.
   • Example: Routine cancer screening (e.g., screening mammography, Pap smears, colonoscopy), blood pressure and lipid screening, and treating latent tuberculosis.
4. Tertiary Prevention:
   • Targets patients with established clinical disease to minimize disability, prevent complications, and maximize rehabilitation.
   • Example: Cardiac rehabilitation post-myocardial infarction, prescribing insulin to prevent diabetic retinopathy, and regular diabetic foot exams to prevent neuropathic ulcers.
5. Quaternary Prevention:
   • Focuses on identifying patients at risk of over-medicalization to protect them from unnecessary, invasive diagnostic or therapeutic interventions.
   • Example: Restricting unnecessary screening tests in low-risk individuals or avoiding unnecessary radiological imaging.